Christopher P. Vellano

4.9k total citations
31 papers, 1.2k citations indexed

About

Christopher P. Vellano is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Christopher P. Vellano has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Christopher P. Vellano's work include Cancer, Hypoxia, and Metabolism (5 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and PARP inhibition in cancer therapy (4 papers). Christopher P. Vellano is often cited by papers focused on Cancer, Hypoxia, and Metabolism (5 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and PARP inhibition in cancer therapy (4 papers). Christopher P. Vellano collaborates with scholars based in United States, China and Austria. Christopher P. Vellano's co-authors include Gordon B. Mills, John R. Hepler, Kang Jin Jeong, Joseph R. Marszalek, Zhenlin Ju, Lorenzo Federico, Yiling Lu, Jun‐Jie Yin, Guang Peng and Shiaw‐Yih Lin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Christopher P. Vellano

31 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher P. Vellano United States	16	798	502	207	144	137	31	1.2k
Douglas Strathdee United Kingdom	18	1.0k 1.3×	297 0.6×	342 1.7×	221 1.5×	192 1.4×	40	1.6k
Markus Reschke Austria	16	938 1.2×	542 1.1×	226 1.1×	195 1.4×	358 2.6×	31	1.7k
Klaus Edvardsen Denmark	24	781 1.0×	419 0.8×	282 1.4×	185 1.3×	125 0.9×	40	1.6k
Marco Gymnopoulos United States	13	835 1.0×	262 0.5×	143 0.7×	158 1.1×	61 0.4×	16	1.2k
Siao Ping Tsai United States	14	997 1.2×	623 1.2×	189 0.9×	233 1.6×	76 0.6×	20	1.9k
Myles Fennell United States	14	924 1.2×	338 0.7×	137 0.7×	225 1.6×	355 2.6×	26	1.6k
Valeria Berno Italy	21	797 1.0×	236 0.5×	155 0.7×	76 0.5×	155 1.1×	33	1.4k
Maura Sonego Italy	14	600 0.8×	303 0.6×	286 1.4×	115 0.8×	60 0.4×	18	937
Yifeng Lin China	19	726 0.9×	184 0.4×	377 1.8×	83 0.6×	231 1.7×	42	1.4k
Heike Peterziel Germany	23	816 1.0×	354 0.7×	242 1.2×	226 1.6×	131 1.0×	46	1.7k

Countries citing papers authored by Christopher P. Vellano

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Vellano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Vellano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Vellano more than expected).

Fields of papers citing papers by Christopher P. Vellano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Vellano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Vellano. The network helps show where Christopher P. Vellano may publish in the future.

Co-authorship network of co-authors of Christopher P. Vellano

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher P. Vellano. A scholar is included among the top collaborators of Christopher P. Vellano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher P. Vellano. Christopher P. Vellano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robesti, Daniele, Eva Corey, Mark Titus, et al.. (2022). Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer. Molecular Cancer Research. 21(1). 51–61. 7 indexed citations

Thomas, Huw D., Yan Zhao, Rachel Howarth, et al.. (2022). Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. British Journal of Cancer. 127(5). 937–947. 28 indexed citations

Donati, Giulio, Micol Ravà, M. Filipuzzi, et al.. (2021). Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma. Molecular Oncology. 16(5). 1132–1152. 10 indexed citations

Hofmann, Marco H., Hengyu Lu, Daniel Gerlach, et al.. (2021). Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.. Cancer Research. 81(13_Supplement). CT210–CT210. 13 indexed citations

Chen, Dawei, Hampartsoum B. Barsoumian, Grant M. Fischer, et al.. (2020). Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. Journal for ImmunoTherapy of Cancer. 8(1). e000289–e000289. 69 indexed citations

Rader, Janet S., Amy Pan, Yiling Lu, et al.. (2019). Identification and validation of a prognostic proteomic signature for cervical cancer. Gynecologic Oncology. 155(2). 324–330. 6 indexed citations

Wang, Zebin, Kaiming Sun, Yonghong Xiao, et al.. (2019). Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific Reports. 9(1). 1853–1853. 178 indexed citations

Yap, Timothy A., Jordi Rodón, Sarina A. Piha‐Paul, et al.. (2019). Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3014–3014. 45 indexed citations

Aslan, Burcu, Mikhila Mahendra, Michael Peoples, et al.. (2019). Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro. 317–317. 1 indexed citations

10.

Sun, Chaoyang, Jun‐Jie Yin, Yong Fang, et al.. (2018). BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 33(3). 401–416.e8. 205 indexed citations

11.

Lee, Jin‐Ho, Gary Geiss, Gokhan Demirkan, et al.. (2018). Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. Molecular & Cellular Proteomics. 17(6). 1245–1258. 16 indexed citations

12.

Ip, Carman Ka Man, Patrick Kwok‐Shing Ng, Kang Jin Jeong, et al.. (2018). Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nature Communications. 9(1). 4583–4583. 43 indexed citations

13.

Fang, Yong, Jun‐Jie Yin, Jian Chen, et al.. (2017). Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine. 9(392). 170 indexed citations

14.

McGrail, Daniel J., Curtis Chun-Jen Lin, Jeannine Garnett, et al.. (2017). Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. npj Systems Biology and Applications. 3(1). 8–8. 39 indexed citations

15.

Federico, Lorenzo, Kang Jin Jeong, Christopher P. Vellano, & Gordon B. Mills. (2015). Thematic Review Series: Phospholipases: Central Role in Lipid Signaling and Disease Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. Journal of Lipid Research. 57(1). 25–35. 39 indexed citations

16.

McCoy, Kelly L., Stefka Gyoneva, Christopher P. Vellano, et al.. (2012). Protease-activated receptor 1 (PAR1) coupling to Gq/11 but not to Gi/o or G12/13 is mediated by discrete amino acids within the receptor second intracellular loop. Cellular Signalling. 24(6). 1351–1360. 37 indexed citations

17.

Vellano, Christopher P., Nicole Brown, J Blumer, & John R. Hepler. (2012). Assembly and Function of the Regulator of G protein Signaling 14 (RGS14)·H-Ras Signaling Complex in Live Cells Are Regulated by Gαi1 and Gαi-linked G Protein-coupled Receptors. Journal of Biological Chemistry. 288(5). 3620–3631. 37 indexed citations

18.

Vellano, Christopher P., Sarah E. Lee, Serena M. Dudek, & John R. Hepler. (2011). RGS14 at the interface of hippocampal signaling and synaptic plasticity. Trends in Pharmacological Sciences. 32(11). 666–674. 27 indexed citations

19.

Vellano, Christopher P., et al.. (2011). G Protein-coupled Receptors and Resistance to Inhibitors of Cholinesterase-8A (Ric-8A) Both Regulate the Regulator of G Protein Signaling 14 (RGS14)·Gαi1 Complex in Live Cells. Journal of Biological Chemistry. 286(44). 38659–38669. 27 indexed citations

20.

Vellano, Christopher P., et al.. (2010). Activation of the Regulator of G Protein Signaling 14−Gαi1-GDP Signaling Complex Is Regulated by Resistance to Inhibitors of Cholinesterase-8A. Biochemistry. 50(5). 752–762. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact